PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Pegulicianine→

Pegulicianine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2230217-17-9
Molecular formula
C118H151N19O24S4.(C2H4O)n
Molecular weight
Not verified g/mol
Drug class
Optical fluorescence imaging agentprotease-activated peptide-dye conjugate
Mechanism of action
After intravenous administration, proteolytic cleavage in the tumour microenvironment activates the pegulicianine fluorophore. The activated fluorophore emits near-infrared fluorescence when illuminated, enabling intraoperative visualisation of residual cancerous tissue in the lumpectomy cavity.
Indications / reported uses
  • Adjunct fluorescence imaging in adults with breast cancer to assist intraoperative detection of cancerous tissue within the resection cavity after removal of the primary specimen during lumpectomy surgery; used with an approved fluorescence imaging system.

Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=7160e774-663a-43e4-ba4a-06cc57830e66&type=display · https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-imaging-drug-assist-detection-cancerous-tissue-following-lumpectomy · https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lumisight · DailyMed

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Pegulicianine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pegulicianine Permitted Daily Exposure (PDE) report (the Pegulicianine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pegulicianine Occupational Exposure Limit (OEL) report (the Pegulicianine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.